Patent perspectives for corticosteroids based ophthalmic therapeutics

Area of Science:

• Ophthalmology
• Pharmaceutics
• Nanotechnology

Background:

• Untreated eye inflammation risks vision loss, with corticosteroids being primary treatments for conditions like uveitis and AMD.
• Conventional ophthalmic corticosteroids face challenges including low bioavailability and systemic toxicity due to precorneal barriers and rapid drainage.
• Non-steroidal anti-inflammatory drugs (NSAIDs) are alternatives, but corticosteroids remain preferred for potent anti-inflammatory effects in ocular conditions.

Purpose of the Study:

• To review clinical findings and patents on corticosteroid use in ocular therapeutics.
• To explore novel drug delivery systems for enhanced ophthalmic corticosteroid efficacy.
• To address limitations of conventional corticosteroid formulations in treating eye inflammation.

Main Methods:

• Literature review of clinical studies and patent databases focusing on corticosteroid ocular formulations.
• Analysis of novel drug delivery systems including nanoparticles, liposomes, and ocular implants.
• Evaluation of nanocarrier-based topical delivery systems for ophthalmic applications.

Main Results:

• Corticosteroids remain a cornerstone for managing diverse ocular inflammatory diseases.
• Novel formulations like nanoparticles, SLN, NLC, and liposomes show promise in overcoming bioavailability issues.
• Topical nanocarriers are identified as effective vectors for ophthalmic drug delivery, enhancing therapeutic outcomes.

Conclusions:

• Novel corticosteroid formulations significantly improve ocular drug bioavailability and reduce systemic toxicity.
• Nanotechnology-based delivery systems represent a promising advancement in ophthalmic pharmacotherapeutics.
• Continued research and patenting of innovative corticosteroid delivery methods are crucial for combating vision-threatening eye inflammation.